Yuan, Yaxia
University of Florida
8 papers on CoChatORCID 0000-0001-7094-4419
Most cited papers
- Verified
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine
Protein Degradation and InhibitorsCell death mechanisms and regulation
Cited by 688
- Verified
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
He, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications
Protein Degradation and InhibitorsTelomeres, Telomerase, and Senescence
Cited by 280
- Verified
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Khan, S., He, Y., Zhang, X., Yuan, Y., Pu, S., Kong, Q., Zheng, G., & Zhou, D. (2020) · Oncogene
Protein Degradation and InhibitorsUbiquitin and proteasome pathways
Cited by 252
- Verified
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications
Protein Degradation and InhibitorsUbiquitin and proteasome pathways
Cited by 158
- Verified
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology
Protein Degradation and InhibitorsUbiquitin and proteasome pathways
Cited by 126
- Verified
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
Zhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry
Protein Degradation and InhibitorsCell death mechanisms and regulation
Cited by 123
- Verified
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
Zhang, X., He, Y., Zhang, P., Budamagunta, V., Lv, D., Thummuri, D., Yang, Y., Pei, J., Yuan, Y., Zhou, D., et al. (2020) · European Journal of Medicinal Chemistry
Protein Degradation and InhibitorsCell death mechanisms and regulation
Cited by 71
- Verified
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition
Pal, P., Thummuri, D., Lv, D., Liu, X., Zhang, P., Hu, W., Poddar, S. K., Hua, N., Khan, S., Yuan, Y., et al. (2021) · Journal of Medicinal Chemistry
Protein Degradation and InhibitorsCell death mechanisms and regulation
Cited by 60
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free